• In January 2026, Takeda and Halozyme Therapeutics announced a global collaboration and exclusive license granting Takeda access to Halozyme’s ENHANZE drug-delivery technology for use with vedolizumab in ulcerative colitis and Crohn’s disease.
• This agreement highlights how Halozyme is broadening the reach of its ENHANZE platform into established gastrointestinal therapies, potentially changing how patients receive maintenance treatment.
• Next, we’ll examine how this ENHANZE collaboration with Takeda influences Halozyme’s investment narrative and the appeal of its drug-delivery portfolio.

These 12 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

What Is Halozyme Therapeutics' Investment Narrative?

For Halozyme, the core investment story is about a profitable, asset‑light royalty model built around the ENHANZE drug‑delivery platform, supported by strong margins and an active buyback program. The new Takeda collaboration on vedolizumab fits cleanly into this narrative by adding another established therapy to the ENHANZE roster, which could modestly reinforce the near‑term revenue and royalty outlook if development progresses as planned. In the short term, investors are still focused on execution against 2025 guidance, the cadence of partner launches such as VYVGART Hytrulo in CIDP, and Halozyme’s ability to keep growing high‑quality earnings while managing its enlarged credit facility conservatively. The biggest risk remains concentration in a partner‑driven model where timing, regulatory outcomes and any slowdown in ENHANZE uptake are largely outside Halozyme’s direct control.

However, one key risk around Halozyme’s reliance on partners deserves closer attention from investors. Despite retreating, Halozyme Therapeutics' shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Eight fair value estimates from the Simply Wall St Community span roughly US$77 to just under US$200, underlining how far apart private investors can be. Set this against Halozyme’s partner concentration risk and ENHANZE dependence, and it becomes even more important to weigh several viewpoints before deciding how the stock fits your portfolio.

Explore 8 other fair value estimates on Halozyme Therapeutics - why the stock might be worth over 2x more than the current price!

Build Your Own Halozyme Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Halozyme Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Halozyme Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Halozyme Therapeutics' overall financial health at a glance.

No Opportunity In Halozyme Therapeutics?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• We've found 13 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 32 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.